Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07444983) titled 'Rezvilutamide for High-Risk Prostate Cancer After Surgery' on Feb. 24.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Fujian Medical University Union Hospital

Condition: Prostate Cancer (Adenocarcinoma)

Intervention: Drug: Rezvilutamide and Leuprorelin

Recruitment Status: Not recruiting

Phase: N/A

Date of First Enrollment: February 11, 2026

Target Sample Size: 33

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07444983

Published by H...